Analysts’ Opinions Are Mixed on These Healthcare Stocks: Dianthus Therapeutics (DNTH), Eli Lilly & Co (LLY) and Haemonetics (HAE)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dianthus Therapeutics (DNTH – Research Report), Eli Lilly & Co (LLY – Research Report) and Haemonetics (HAE – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dianthus Therapeutics (DNTH)
Truist Financial analyst Danielle Brill maintained a Buy rating on Dianthus Therapeutics today. The company’s shares closed last Thursday at $44.00.
According to TipRanks.com, Brill is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dianthus Therapeutics with a $59.17 average price target, implying a 27.8% upside from current levels. In a report issued on January 14, William Blair also reiterated a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Eli Lilly & Co (LLY)
In a report released today, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Eli Lilly & Co, with a price target of $1265.00. The company’s shares closed last Thursday at $1032.97.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $1192.00, which is a 12.2% upside from current levels. In a report issued on January 2, DBS also maintained a Buy rating on the stock with a $1333.00 price target.
Haemonetics (HAE)
In a report released today, Travis Steed from Bank of America Securities maintained a Hold rating on Haemonetics, with a price target of $90.00. The company’s shares closed last Thursday at $74.00.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
Currently, the analyst consensus on Haemonetics is a Moderate Buy with an average price target of $88.86, implying a 17.7% upside from current levels. In a report issued on January 9, Needham also maintained a Hold rating on the stock.
